Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells

Breast Cancer Research

Volumn 12, Issue 4, 2010, Pages

  Brüning, Ansgar ^a,b   Friese, Klaus ^a,b   Burges, Alexander ^b   Mylonas, Ioannis ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; GLUTATHIONE; NELFINAVIR; TAMOXIFEN; ACTIVATING TRANSCRIPTION FACTOR 3; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ATF3 PROTEIN, HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; OXIDATIVE STRESS; BREAST TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; FEMALE; METABOLISM; PATHOLOGY; TIME; TUMOR CELL LINE; WESTERN BLOTTING;

ACTIVATING TRANSCRIPTION FACTOR 3; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; AUTOPHAGY; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; GLUTATHIONE; HIV PROTEASE INHIBITORS; HUMANS; NELFINAVIR; POLY(ADP-RIBOSE) POLYMERASES; TAMOXIFEN; TIME FACTORS;

EID: 78650873029     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2602     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20:1319-1329. 10.1093/annonc/mdp322, 2720818, 19535820.
3. Fisher B, Redmond C. Systemic therapy in node-negative patients: updated findings from NSABP clinical trials. National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst Monogr 1992, 11:105-116.
4. Howell A. The endocrine prevention of breast cancer. Best Pract Res Clin Endocrinol Metab 2008, 22:615-623. 10.1016/j.beem.2008.09.002, 18971122.
5. Harichand-Herdt S, Zelnak A, O'Regan R. Endocrine therapy for the treatment of postmenopausal women with breast cancer. Expert Rev Anticancer Ther 2009, 9:187-198. 10.1586/14737140.9.2.187, 19192957.
6. Gundimeda U, Chen ZH, Gopalakrishna R. Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells. J Biol Chem 1996, 271:13504-13514. 10.1074/jbc.271.23.13504, 8662863.
7. Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001, 6:469-477. 10.1023/A:1012437607881, 11595837.
8. Pore N, Gupta AK, Cerniglia GJ, Maity A. HIV protease inhibitors decrease VEGF/HIF-1α expression and angiogenesis in glioblastoma cells. Neoplasia 2006, 8:889-895. 10.1593/neo.06535, 1716015, 17132220.
9. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007, 13:5183-5194. 10.1158/1078-0432.CCR-07-0161, 17785575.
10. Cohen J. Biomedicine. HIV drug shows promise as potential cancer treatment. Science 2007, 317:1305. 10.1126/science.317.5843.1305, 17823319.
11. Plastaras JP, Vapiwala N, Ahmed MS, Gudonis D, Cerniglia GJ, Feldman MD, Frank I, Gupta AK. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther 2008, 7:628-635.
12. Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008, 26:2699-2706. 10.1200/JCO.2007.15.2355, 18509182.
13. Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future?. Lancet Oncol 2009, 10:61-71. 10.1016/S1470-2045(08)70334-6, 19111246.
14. Pyrko P, Kardosh A, Wang W, Xiong W, Schonthal AH, Chen TC. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 2007, 67:10920-10928. 10.1158/0008-5472.CAN-07-0796, 18006837.
15. Bruning A, Burger P, Vogel M, Rahmeh M, Gingelmaiers A, Friese K, Lenhard M, Burges A. Nelfinavir induces the unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis. Cancer Biol Ther 2009, 8:226-232.
16. Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia 2007, 9:271-278. 10.1593/neo.07124, 1854844, 17460771.
17. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2000, 2:326-332. 10.1038/35014014, 10854322.
18. Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 2005, 35:373-381. 10.1016/j.ymeth.2004.10.010, 15804610.
19. Fribley A, Wang CY. Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther 2006, 5:745-748.
20. Fels DR, Koumenis C. The PERK/eIF2α/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol Ther 2006, 5:723-728. 10.1158/1535-7163.MCT-05-0164, 16861899.
21. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, Shokat KM, Lavail MM, Walter P. IRE1 signaling affects cell fate during the unfolded protein response. Science 2007, 318:944-949. 10.1126/science.1146361, 17991856.
22. Boelens J, Lust S, Offner F, Bracke ME, Vanhoecke BW. Review. The endoplasmic reticulum: a target for new anticancer drugs. In Vivo 2007, 21:215-226.
23. Regazzi MB, Villani P, Maserati R, Seminari E, Pan A, LoCaputo F, Gambarana E, Fiocchi C. Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients. J Antimicrob Chemother 2000, 45:343-347. 10.1093/jac/45.3.343, 10702554.
24. Regazzi MB, Seminari E, Villani P, Carriero PL, Montagna M, Marubbi F, Maserati R. Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profile. J Chemother 2001, 13:569-574.
25. Kaldor SW, Kalish VJ, Davies JF, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH. Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem 1997, 40:3979-3985. 10.1021/jm9704098, 9397180.
26. Bruning A, Burger P, Vogel M, Gingelmaier A, Friese K, Burges A. Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib. Invest New Drugs 2009,
27. Franco R, Cidlowski JA. Apoptosis and glutathione: beyond an antioxidant. Cell Death Differ 2009, 16:1303-1314. 10.1038/cdd.2009.107, 19662025.
28. Schmidtke G, Holzhutter HG, Bogyo M, Kairies N, Groll M, de Giuli R, Emch S, Groettrup M. How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 1999, 274:35734-35740. 10.1074/jbc.274.50.35734, 10585454.
29. Bruning A, Rahmeh M, Gingelmaier A, Friese K. The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization. Mol Cancer 2010, 9:19. 10.1186/1476-4598-9-19, 2836985, 20105315.
30. Bruning A, Vogel M, Burger P, Rahmeh M, Gingelmaier A, Friese K, Lenhard M, Burges A. Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells. Biochem Biophys Res Commun 2008, 377:1309-1314. 10.1016/j.bbrc.2008.10.167, 19000651.
31. Scriven P, Coulson S, Haines R, Balasubramanian S, Cross S, Wyld L. Activation and clinical significance of the unfolded protein response in breast cancer. Br J Cancer 2009, 101:1692-1698. 10.1038/sj.bjc.6605365, 2778547, 19861963.
32. Andersson H, Helmestam M, Zebrowska A, Olovsson M, Brittebo E. Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos 2010, 38:200-207. 10.1124/dmd.109.029488, 19812351.
33. Wek RC, Jiang HY, Anthony TG. Coping with stress: eIF2 kinases and translational control. Biochem Soc Trans 2006, 34:7-11. 10.1042/BST0340007, 16246168.
34. Hu P, Han Z, Couvillon AD, Exton JH. Critical role of endogenous Akt/IAPs and MEK1/ERK pathways in counteracting endoplasmic reticulum stress-induced cell death. J Biol Chem 2004, 279:49420-49429. 10.1074/jbc.M407700200, 15339911.
35. Matthews JA, Belof JL, Acevedo-Duncan M, Potter RL. Glucosamine-induced increase in Akt phosphorylation corresponds to increased endoplasmic reticulum stress in astroglial cells. Mol Cell Biochem 2007, 298:109-123. 10.1007/s11010-006-9358-5, 17136481.
36. Jiang CC, Yang F, Thorne RF, Zhu BK, Hersey P, Zhang XD. Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. Neoplasia 2009, 11:436-447. 2671856, 19412428.
37. Price J, Zaidi AK, Bohensky J, Srinivas V, Shapiro IM, Ali H. Akt-1 mediates survival of chondrocytes from endoplasmic reticulum-induced stress. J Cell Physiol 2010, 222:502-508.
38. Hosoi T, Hyoda K, Okuma Y, Nomura Y, Ozawa K. Akt up- and down-regulation in response to endoplasmic reticulum stress. Brain Res 2007, 1152:27-31. 10.1016/j.brainres.2007.03.052, 17434462.
39. Dai R, Chen R, Li H. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. Int J Oncol 2009, 34:1749-1757.